<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20448">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840695</url>
  </required_header>
  <id_info>
    <org_study_id>bDMARD AS Spinal Fractures</org_study_id>
    <nct_id>NCT02840695</nct_id>
  </id_info>
  <brief_title>Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)</brief_title>
  <official_title>Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ankylosing spondylitis (AS) is a rheumatoid disease affecting all segments of the axial
      skeleton, leading to the complete fusion of all spinal segments - the bamboo-spine. During
      the last decade biological disease modifying anti-rheumatic drugs (bDMARD) have been
      successfully introduced to reduce the disease activity. It is unclear whether bDMARD
      treatment had an effect on spinal fracture risk related to AS. This national registry study
      will investigate the effect of bDMARD treatment on spinal fracture risk in a national cohort
      of patients with AS.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Spinal fracture</measure>
    <time_frame>10 years</time_frame>
    <description>Censored data with occurrence of spinal fracture within 10 years observation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9858</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Spinal Fractures</condition>
  <arm_group>
    <arm_group_label>AS patients</arm_group_label>
    <description>Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bDMARD treatment</intervention_name>
    <description>Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.</description>
    <arm_group_label>AS patients</arm_group_label>
    <other_name>Biological Disease Modifying Drug treatment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with AS as registered in the Swedish Patient Registry with ICD-9-code 720 or
        ICD-10 code M45.9.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 30-60 years

          -  registered diagnosis of ankylosing spondylitis

        Exclusion Criteria:

          -  age &lt;30 or &gt;60 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 18, 2016</lastchanged_date>
  <firstreceived_date>July 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
